secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001104659-24-001799
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio reports $142M cash, extends runway to Q4 2025, details 2024 milestones
--------------------------------------------------------------------------------

- Preliminary cash and equivalents: $142M as of Dec 31, 2023; ~38.6M ordinary shares outstanding.
- Cash runway extended from Q2 to Q4 2025 by deferring VTP-1100 IND in HPV cancer and phasing manufacturing.
- H1 2024: initiate Phase 1 trial of VTP-1000 in Celiac Disease; final Phase 1b/2 VTP-200 (HPV) data.
- H1 2024: interim data from HBV003 (Phase 2b VTP-300 dosing) and AB-729-202 (VTP-300 + imdusiran) trials.
- H2 2024: interim data from third arm of AB-729-202 adding nivolumab to VTP-300 and imdusiran.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465924001799/0001104659-24-001799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465924001799/tm242118d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-001799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer